| Serial Number | 90151432 |
| Word Mark | ÆTERNA ZENTARIS |
| Filing Date | Tuesday, September 1, 2020 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, June 29, 2021 |
| Registration Number | 6400616 |
| Registration Date | Tuesday, June 29, 2021 |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, April 13, 2021 |
| Indication of Colors claimed | The color(s) azure and dark lime green is/are claimed as a feature of the mark. |
| Goods and Services | Pharmaceutical preparations used for the treatment of cancer; pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer; pharmaceutical preparations used for the treatment of urological diseases; pharmaceutical preparations used for the treatment of hormonal disorders; synthetic peptides-containing pharmaceutical preparations used for hormonal and tumors treatments; pharmaceutical preparations used for the treatment of endocrine diseases; pharmaceutical preparations used for the treatment of carcinoid tumors; pharmaceutical preparations used for the treatment of haematological diseases; pharmaceutical preparations used for the treatment of age-related diseases; pharmaceutical preparations used for the treatment of ophthalmological disorders; pharmaceutical preparations used for the treatment of reproductive system disorders; pharmaceutical preparations used for the treatment of endometriosis; pharmaceutical preparations used for the treatment of uterine myoma; pharmaceutical preparations used for the treatment of non-malignant tumors; pharmaceutical preparations used for the treatment of benign prostatic hyperplasia; pharmaceutical preparations used for the treatment of tropical diseases; pharmaceutical preparations used for the treatment of infectious disease; pharmaceutical preparations used for the treatment of leishmaniasis; pharmaceutical preparations used for the treatment of obesity; pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes; pharmaceutical preparations containing cytotoxic products, conjugated or not, for the treatment of cancer or infectious diseases; pharmaceutical preparations used as a tubulin inhibitor for the treatment of cancer; pharmaceutical preparations based on LHRH antagonists platform for the treatment of cancer, hormonal tumors, or hormonal disorders; pharmaceutical preparations based on bombesin antagonist platform for the treatment of cancer; pharmaceutical preparations based on inhibitors of the Akt pathway for the treatment of cancer or infectious diseases; pharmaceutical preparations based on angiogenesis inhibitors platform for the treatment of cancer; pharmaceutical preparations used to induce apoptosis; pharmaceutical preparations used to stimulate growth hormone secretagogue; vaccines for the treatment of tumors; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of respiratory diseases; pharmaceutical preparations for the treatment of gastrointestinal diseases; diagnostic agents, preparations and substances for medical purposes; pharmaceutical products, comprising growth hormone secretagogues, ghrelin receptor agonists, ghrelin receptor antagonists, ghrelin mimetics, growth hormone analogues, growth hormone fusion proteins, growth hormone releasing hormone analogues, auto immune modulating proteins, therapeutic antibodies, small molecule kinase inhibitors, phospholipids for the treatment of neurological disorders; pharmaceutical preparations for the treatment of nasopharyngeal disorders; antibiotics; antibacterial and fungicidal preparations; pharmaceutical preparations for the treatment of mental health; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of rheumatoid diseases; pharmaceutical preparations for contraceptives and women's health; analgesic pharmaceutical products, comprising small molecule kinase inhibitors, phospholipids, therapeutic antibodies, natural products; sedativa and pharmaceutical preparations for the treatment of psychiatric disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for palliative treatments; pharmaceutical preparations for the treatment of addictions; pharmaceutical formulations for the treatment of paediatric indications |
| Description of Mark | The mark consists of a stylized wavy line in the shape of a sideways infinity symbol on a slight tilt to the right with the tail ends in azure and the middle swoop in dark lime green followed by the word "ÆTERNA" in thin dark lime green letters above the word "ZENTARIS" in thick azure letters. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, October 6, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Æterna Zentaris GmbH |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | Frankfurt am Main 60314 DE |
| Party Name | Æterna Zentaris GmbH |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Frankfurt am Main 60314 DE |
| Party Name | Æterna Zentaris GmbH |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Frankfurt am Main 60314 DE |
| Event Date | Event Description |
| Friday, September 4, 2020 | NEW APPLICATION ENTERED |
| Tuesday, October 6, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, October 7, 2020 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Wednesday, January 6, 2021 | ASSIGNED TO EXAMINER |
| Tuesday, January 12, 2021 | NON-FINAL ACTION WRITTEN |
| Tuesday, January 12, 2021 | NON-FINAL ACTION E-MAILED |
| Tuesday, January 12, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, February 26, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, February 26, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, February 26, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, March 1, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, March 5, 2021 | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED |
| Wednesday, March 10, 2021 | ELECTRONIC RECORD REVIEW COMPLETE |
| Wednesday, March 24, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, April 13, 2021 | PUBLISHED FOR OPPOSITION |
| Tuesday, April 13, 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, June 29, 2021 | REGISTERED-PRINCIPAL REGISTER |
| Monday, June 29, 2026 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |